Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNTech SE (BNTX – Research Report), Connect Biopharma Holdings (CNTB – Research Report) and Clene (CLNN – Research Report) with bullish sentiments.
BioNTech SE (BNTX)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on BioNTech SE, with a price target of $107.00. The company’s shares closed last Tuesday at $86.34, close to its 52-week low of $85.21.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $111.64 average price target, implying a 29.2% upside from current levels. In a report issued on April 9, BMO Capital also assigned a Buy rating to the stock with a $123.00 price target.
See today’s best-performing stocks on TipRanks >>
Connect Biopharma Holdings (CNTB)
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Connect Biopharma Holdings today and set a price target of $8.00. The company’s shares closed last Tuesday at $1.73.
According to TipRanks.com, Bodnar is a 4-star analyst with an average return of
Connect Biopharma Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $7.00, a 326.8% upside from current levels. In a report issued on April 9, Leerink Partners also reiterated a Buy rating on the stock with a $6.00 price target.
Clene (CLNN)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Clene, with a price target of $7.00. The company’s shares closed last Tuesday at $0.31, close to its 52-week low of $0.25.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clene with a $4.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNTX:
- BioNTech SE Virtual AGM Scheduled for May 2024
- BioNTech Reports Promising Cancer Vaccine Data
- BioNTech announces Phase 1 trial follow up data for mRNA-based iNeST candidate
- Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
- BioNTech price target lowered to $101 from $110 at UBS
